the clinical impact of gene expression assays on early luminal breast cancer
Published 2 years ago • 341 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
5:54
roxane: impact of 21-gene assay on treatment for early breast cancer
-
1:19
gene expression assays to identify patients with breast cancer for neoadjuvant treatment
-
0:38
rxponder: 21-gene assay informs chemotherapy benefit in hr node-positive breast cancer
-
5:34
tailorx: phase 3 trial validating a 21-gene expression assay in breast cancer
-
1:35
gene expression profiling of breast cancer brain mets shows enrichment for non-luminal subtypes
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
1:12
impact of genomic testing on treatment decision-making in breast cancer
-
2:13
n9831 trial: genes associated with early and late recurrence in her2 breast cancer
-
0:40
assessing the role of 21-gene assays in breast cancer
-
8:22
molecular profiling in early breast cancer
-
5:16
master regulators of luminal and basal subtypes of breast cancer - archana iyer - recomb/rsg 2014
-
1:36
ctdna assay for detection of recurrent disease in patients with early-stage breast cancer
-
28:11
2021 mdons | the nurses role in early stage breast cancer | a focus on genomic assays
-
1:08
the role of immunotherapy in endocrine-refractory luminal breast cancer
-
1:23
exploring myeloid cells to reverse the hormone-mediated microenvironemnt of luminal breast cancer
-
1:49
early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?
-
4:11
the latest in neo-adjuvant therapy for luminal breast cancer
-
1:47
can we decrease chemotherapy in ln premenopausal women based on genomic tests?
-
1:25
genomic profiling for defining luminal subtypes